EC Dental Science

Metronidazole is nitroimidazole antibiotic medication which has a specific activity against anaerobic bacteria and protozoa. In cardiology, the QT interval represents electrical depolarization and repolarization of the ventricles. A lengthened QT interval is a marker for the potential of ventricular tachyarrhythmia. Rare cases have been reported with QT prolongation in which metronidazole antibiotic had been used. The arrythmogenic prop- erties of metronidazole is not yet clear.

This case reports a 10-year-old male child of 30 kg body weight with no history of any chronic illness or drug allergy came to the dental clinic with facial swelling, which was diagnosed as dental abscess. He was given oral metronidazole (500 mg 3 times/day for 5 days).

On the third day, he presented to the emergency department with palpitation, vomiting and then he collapsed. Cardiac Pulmonary Recitation (CPR) done and Electrocardiogram (ECG) showed prolonged QT corrected interval (QTc 480 ms). Laboratory test including serum potassium, magnesium and liver functional tests were within normal. Metronidazole was im- mediately stopped and subsequently the ECG retained to normal.

In Conclusion, Metronidazole can potentiate QT prolongation. Further investigation should be carried out to assess its potential effect on QT interval and subsequent lethal arrhythmias. The maximum pediatric dose should be reviewed.

Keywords: Metronidazole; QT Prolongation; ECG

1. Cooke C., et al. “Possible pharmacokinetic interaction with quinidine: ciprofloxacin or metronidazole?” Annals of Pharmacotherapy4 (1996): 364-366.v
2. Kounas S., et al. “QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone”. Pacing and Clinical Electrophysiology5 (2005): 427-473.
3. Fehri W., et al. “Short coupled variant of torsade de pointes: our experience and review of the literature”. La Tunisie Medicale9 (2004): 867-874.
4. Viskin S., et al. “Long QT syndrome caused by noncardiac drugs”. Progress in Cardiovascular Diseases5 (2003): 415-427.
5. De Ponti F., et al. “Organizing evidence on QT prolongation and occurrence of torsades de pointes with non-antiarrhythmic drugs: a call for concensus”. European Journal of Clinical Pharmacology3 (2010): 185-209.
6. Roden D. “Taking the “idio” out of “idiosyncratic”. Predicting torsades de pointes”. Pacing and Clinical Electrophysiology5 (1998): 1029-1034.
7. Armahizer M., et al. “Drug-drug interactions contributing to QT Prolongation in cardiac intensive care units”. Journal of Critical Care3 (2013): 243-249.
8. Chohen O., et al. “First Report of metronidazole-induced QT interval prolongation”. International Journal of Antimicrobial Agents2 (2008): 180-181.
9. Altin C., et al. “QT interval prolongation due to metronidazole administration”. Anadolu Kardiyoloji Dergisi5 (2011): 468-469.
10. Pandarunga P., et al. “Multi-factorial causes of torsade de pontes in a hospitalized surgical patient”. Sultan Qaboos University Medical Journal1 (2013): 152-155.
11. Ellison SJ. “The role of phenoxymethylpenicillin, amoxicillin, metronidazole and clindamycin in the management of acute dentoalveolar abscesses-a review”. British Dental Journal7 (2009): 357-362.
12. Poluzzi E., et al. “Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System”. Drug Safety4 (2010): 303-314.
13. Napolitano C., et al. “Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias”. Journal of Cardiovascular Electrophysiology6 (2000): 691-696.v
14. Zeltser D., et al. “Torsade de pointes due to non-cardiac drugs: most patients have easily identifiable risk factors”. Medicine (Balti more)4 (2003): 282-290.